Skip to main content
NCBI home page
World Journal of Gastroenterology logoLink to World Journal of Gastroenterology
. 2005 Aug 7;11(29):4604–4606. doi: 10.3748/wjg.v11.i29.4604

Alterations of serum cholinesterase in patients with gastric cancer

Shan-Zhi Gu 1,2, Xin-Han Zhao 1,2, Ping Quan 1,2, Sheng-Bin Li 1,2, Bo-Rong Pan 1,2
PMCID: PMC4398718  PMID: 16052698

Abstract

AIM: To understand the correlation of serum cholinesterase (CHE) activity with gastric cancer and to assess their clinical significance.

METHODS: The velocity method was adopted to detect the activity of serum CHE in patients with gastric cancer and in patients with non-malignant tumor as controls.

RESULTS: The serum CHE activity in the treatment group was significantly lower than that in the control group with a very significant difference between the two groups (83.3:113.1,P = 0.0003). Age was significantly associated with the incidence of gastric caner.

CONCLUSION: Serum CHE activity has a close relation with the incidence of gastric cancer.

Keywords: Cholinesterase activity, Gastric cancer

INTRODUCTION

CHE is a type of glycoprotein[1-4], existing in vivo in multiple forms of isozyme[5-7]. The decrease of serum CHE activity is often observed in patients with organic phosphorus poisoning[8] and damage of parenchymal cells[9-12]. In clinical practice, we have discovered that there is a decrease of serum CHE activity in patients with gastric cancer. This study aimed to detect the serum CHE activity in patients with gastric cancer, and to observe the correlation of serum CHE activity with the incidence of gastric cancer.

MATERIALS AND METHODS

Subjects

The treatment group included 81 patients (61 males and 20 females aged 30-80 years with an average age of 58.8±12.0 years) with gastric cancer hospitalized from January 1998 to June 2002. The disease was confirmed by gastroscopic examination and/or pathological examination. Clinical and pathologic classifications followed the General Rules for Gastric Cancer Study in Surgery and Pathology in Japan. The control group included 80 patients (44 males and 36 females) with non-malignant tumor hospitalized during the same period. Their age ranged 26-86 years with an average age of 57.7±15.3 years. Patients with organic phosphorus poisoning or damage of parenchymal cells were excluded.

Methods

All the patients were fasted for more than 12 h, then venous blood was taken. After centrifugation, serum was subjected to detection on the same day. Serum CHE activity was measured by the velocity method with Hitachi 7170 full automatic biochemical instrument and Hitachi 7170 special reagent. The normal reference value was 75-217 μkat/L.

Statistical analysis

All the data were fed into a computer. The SPSS10.0 software package was employed for analysis and processing. The chi-square test was conducted. With the CHE difference between the gastric cancer group and the control group, F test was adopted. For the purpose of reviewing the relation between sex, age and CHE, the multi-factor regression analysis was conducted with respect to the above three factors. The statistical significance level was defined as <0.05 with two-sided detection.

RESULTS

Serum CHE activity in gastric cancer

The age of the gastric cancer group and control group both expressed abnormal distribution with the mid-value being 60.5 and 61.5 years respectively. The χ2 was performed (χ2 = 22.265, P = 0.0002), suggesting that the age distribution in the two groups was overbalanced. The result from the χ2 detection for the sex distribution was χ2 = 25.138 and P = 0.0003, showing that the sex distribution in the two groups was out of balance as well. Tables 1 and 2 respectively show the co-variance analysis results.

Table 1.

Serum CHE distribution in gastric cancer patients (μkat/L)

Sex Group n Average Standard error 95%Cl
Lower limit Upper limit
Male Gastric cancer 61 81.6 31.5 77.2 86.1
Control 44 114.8 30.8 108.9 120.6
Female Gastric cancer 20 85 34.5 76.2 93.9
Control 36 111.4 25.8 106.2 116.7
Open in a new tab

Table 2.

Covariance analysis results of CHE in gastric cancer patients and controls

Sex Variation source Df Mean square root F P
Male Within group 1 849 712 857.157 256.718 0.000
Age (yr) 4 6 116 906.471 18.481 0.000
Between groups 1 261 709 135.862 79.069 0.000
Error 79 3 309 902.711
Total 85
Female Within group 1 93 519 230.733 29.884 0.000
Age (yr) 3 732 546.506 16.372 0.000
Between groups 1 3 129 425.453 54.081 0.000
Error 61 430 763.233
Total 66
Open in a new tab

The age and nature of gastric cancer patients had a linear correlation with the CHE level (r = 0.8, P = 0.031), suggesting that the difference in CHE level between gastric cancer patients and controls was significant (F = 79.069, P = 0.0004). The serum CHE level of gastric cancer patients (81.6±31.5 μkat/L) was significantly lower than that in the control group (114.8±30.8 μkat/L), indicating that age was also an important factor affecting the incidence of gastric cancer (F = 18.481, P = 0.0003).

With the age distribution, χ2 was performed (χ2 = 5.281, P = 0.383), showing that the age was evenly distributed. In gastric cancer patients and controls, CHE had a normal distribution and the variance was in order. Therefore, single-factor variance analysis could be made. The average value, standard deviation and single-factor variance are listed in Tables 1 and 2.

The difference in CHE levels of the two groups was significant (F = 29.884, P = 0.0006). The serum CHE level in gastric cancer patients (85.0±34.5 μkat/L) was significantly lower than that in the control group (111.4±25.8 μkat/L, Figure 1).

Figure 1.

Figure 1

Open in a new tab

Different CHE levels in gastric cancer patients.

Multi-factor logistic regressive analysis

The three variables (sex, age, and CHE) were put into the Logistic model. After being fitted with the backward method, the final model was expressed (Table 3). The factors put into the model were only sex and CHE. The adaptive regressive equation was P (1) = 1/[1+e-(0.129)+2.542X1+1.006X3] or CHE = 12.701. Therefore, after removing the influence of other factors, the reduction of the CHE activity was a dangerous factor for gastric cancer.

Table 3.

The Logistic analysis of sex and CHE

Variable B SE Wald df Sig. Exp (B) 95.0 (%) CI for exp (B)
Lower Upper
Sex 1.066 0.234 20.825 1 0 2.905 1.837 4.592
CHE 2.542 0.313 66.131 1 0 12.701 6.883 24.435
Constant 16.129 0.697 77.303 1 0 0.002
Open in a new tab

DISCUSSION

Cholinesterase can be divided into true cholinesterase (acetylcholinesterase, ACHE) and pseudocholinesterase (PCHE). ACHE exists mainly in the vesicles of cholinergic nerve peripheral synapse where there is a comparatively large amount of ACHE in the folding of the terminal synapse back membranes. It also exists in the cholinergic neurons[13,14], red cells[15], sera[16], livers[17], kidneys[18], intestines, white mass of brain[19], etc. In the activity center on the surface of the molecules of CHE protein, there are two places to be combined with acetylcholine, namely the anion place with negative charges and the place with ester decomposition. The place with ester decomposition has an acidic action point formed by serine hydroxide and an alkaline action point formed by histidine imidazole ring. They are combined by means of hydrogen bonds. PCHE reduces when the parenchymal cells are damaged, as the liver synthesizes PCHE[20-22]. Organophosphorus toxicant is a powerful inhibitor of ACHE and PCHE[23-26]. Measuring serum CHE activity can help diagnose organophosphorus poisoning and evaluate the condition after recovery. The results of this experiment indicate that human serum CHE activity has a significant correlation with gastric cancer.

Anic et al[27] discovered that the serum CHE activity in hepatitis B patients is relatively low. Khan et al[28] detected serum CHE and lactic dehydrogenase (LDH) activity in 40 cases of mammary cancer patients, 25 cases of benign tumor patients and 30 cases of healthy persons, and found that there is a significant difference in serum CHE activity between malignant and benign tumor patients.

If the ratio between CHE activity and serum CHE activity is less than 0.42, the malignant source should be considered[29]. A number of studies have been conducted on the relation between serum CHE activity and acute leukemia and cervical cancer[30,31].

Among the 81 cases of gastric cancer in the present study, there were 39 cases(48.2%) whose serum CHE activity was less than 75.0 μkat/L. Among the 80 cases of controls, there were only five cases (6.3%) whose serum CHE activity was less than 50.0 μkat/L. In the gastric cancer group, there were 14 cases whose serum CHE activity was less than 75.0 μkat/L. However, in the control group, there were no such cases. The results suggest that if a patient with gastric pathological changes whose serum CHE activity is less than 50.0 μkat/L, sharp vigilance on the existence of gastric cancer should be maintained after organophosphorous poisoning and damages of parenchymal cells, etc., are excluded.

In conclusion, the determination of serum CHE activity is a rapid, simple, convenient, inexpensive and reliable method to diagnose gastric cancer. Its exact mechanism remains to be further explored.

Footnotes

Co-first-authors: Shan-Zhi Gu and Xin-Han Zhao

Science Editor Wang XL and Guo SY Language Editor Elsevier HK

References

  • 1.Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol. 2003;60:958–964. doi: 10.1001/archneur.60.7.958. [DOI] [PubMed] [Google Scholar]
  • 2.Luo ZB, Xu CP, Wang D, Wang G, Xiao SQ, Zhu GY, Fang DC. Immunotherapy of dendritic cells andits exosomes transfected with mRNA of gastric cancer cells in tumor-carriedmice. World Chin J Digestol. 2004;12:9–12. [Google Scholar]
  • 3.Valbonesi P, Sartor G, Fabbri E. Characterization of cholinesterase activity in three bivalves inhabiting the North Adriatic sea and their possible use as sentinel organisms for biosurveillance programmes. Sci Total Environ. 2003;312:79–88. doi: 10.1016/S0048-9697(03)00227-4. [DOI] [PubMed] [Google Scholar]
  • 4.Pelizzi N, Puccini P, Riccardi B, Acerbi D, Catinella S. Characterization of Ganstigmine metabolites in hepatocytes by low- and high-resolution mass spectrometry coupled with liquid chromatography. Rapid Commun Mass Spectrom. 2003;17:1691–1698. doi: 10.1002/rcm.1107. [DOI] [PubMed] [Google Scholar]
  • 5.Sagi Y, Weinstock M, Youdim MB. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J Neurochem. 2003;86:290–297. doi: 10.1046/j.1471-4159.2003.01801.x. [DOI] [PubMed] [Google Scholar]
  • 6.Luo ZB, Xu CP, Zhu GY, Zhang PB, Guo CH, Luo YH, Fang DC, Luo CJ. Immunotherapy of dendritic cells transfected with mRNA of gastric cancer cells in carried-tumor mice. World Chin J Digestol. 2004;12:13–15. [Google Scholar]
  • 7.Marco JL, Carreiras MC. Recent developments in the synthesis of acetylcholinesterase inhibitors. Mini Rev Med Chem. 2003;3:518–524. doi: 10.2174/1389557033487908. [DOI] [PubMed] [Google Scholar]
  • 8.Pascuzzi RM. The edrophonium test. Semin Neurol. 2003;23:83–88. doi: 10.1055/s-2003-40755. [DOI] [PubMed] [Google Scholar]
  • 9.Xin SJ, Zhang LX, Zhu CL, Hu JH, Duan XZ, You SL, Hu LP, Zou ZS, Mao YL, Huangpu YS. Correlation of clinical features with pathology in chronic viral hepatitis. Zhonghua ShiYan He LinChuang BingDuXue ZaZhi. 2003;17:88–90. [PubMed] [Google Scholar]
  • 10.Pepin JL, Myressiotis S, Ceulemans S. Prevention of dementia: is it possible? Rev Med Liege. 2003;58:220–224. [PubMed] [Google Scholar]
  • 11.Androne AS, Hryniewicz K, Goldsmith R, Arwady A, Katz SD. Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure. Heart. 2003;89:854–858. doi: 10.1136/heart.89.8.854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O'Brien JA, Papadopoulos G. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther. 2003;25:1806–1825. doi: 10.1016/s0149-2918(03)80171-6. [DOI] [PubMed] [Google Scholar]
  • 13.Grossberg G, Irwin P, Satlin A, Mesenbrink P, Spiegel R. Rivastigmine in Alzheimer disease: efficacy over two years. Am J Geriatr Psychiatry. 2004;12:420–431. doi: 10.1176/appi.ajgp.12.4.420. [DOI] [PubMed] [Google Scholar]
  • 14.Loewenstein DA, Acevedo A, Czaja SJ, Duara R. Cognitive rehabilitation of mildly impaired Alzheimer disease patients on cholinesterase inhibitors. Am J Geriatr Psychiatry. 2004;12:395–402. doi: 10.1176/appi.ajgp.12.4.395. [DOI] [PubMed] [Google Scholar]
  • 15.Darvesh S, Arora RC, Martin E, Magee D, Hopkins DA, Armour JA. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons. Exp Neurol. 2004;188:461–470. doi: 10.1016/j.expneurol.2004.05.002. [DOI] [PubMed] [Google Scholar]
  • 16.Zdrazilová P, Stepánková S, Komers K, Ventura K, Cegan A. Half-inhibition concentrations of new cholinesterase inhibitors. Z Naturforsch C. 2004;59:293–296. doi: 10.1515/znc-2004-3-430. [DOI] [PubMed] [Google Scholar]
  • 17.van Dyck CH. Understanding the latest advances in pharmacologic interventions for Alzheimer's disease. CNS Spectr. 2004;9:24–28. doi: 10.1017/s1092852900024780. [DOI] [PubMed] [Google Scholar]
  • 18.Eskenazi B, Harley K, Bradman A, Weltzien E, Jewell NP, Barr DB, Furlong CE, Holland NT. Association of in utero organophosphate pesticide exposure and fetal growth and length of gestation in an agricultural population. Environ Health Perspect. 2004;112:1116–1124. doi: 10.1289/ehp.6789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Arai H. Current therapies in dementia. Nihon Ronen Igakkai Zasshi. 2004;41:310–313. doi: 10.3143/geriatrics.41.310. [DOI] [PubMed] [Google Scholar]
  • 20.Kurz A, Van Baelen B. Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration. Dement Geriatr Cogn Disord. 2004;18:217–226. doi: 10.1159/000079388. [DOI] [PubMed] [Google Scholar]
  • 21.Fu G, Wang GB, Lu XM, Huang QX, Zheng H. MAPK signal transduction and apoptosisof human gastric carcinoma cells induced by liposomes of survivin antisense oligonucleotide. World Chin J Digestol. 2004;12:1034–1039. [Google Scholar]
  • 22.Khang P, Weintraub N, Espinoza RT. The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available? J Am Med Dir Assoc. 2004;5:249–255. doi: 10.1097/01.JAM.0000131500.41375.1D. [DOI] [PubMed] [Google Scholar]
  • 23.Sormani MP, Oneto R, Bruno B, Fiorone M, Lamparelli T, Gualandi F, Raiola AM, Dominietto A, Van Lint MT, Frassoni F, et al. A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cell dose. Bone Marrow Transplant. 2003;32:205–211. doi: 10.1038/sj.bmt.1704085. [DOI] [PubMed] [Google Scholar]
  • 24.Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am J Geriatr Psychiatry. 2003;11:458–461. [PubMed] [Google Scholar]
  • 25.Pang YP, Kollmeyer TM, Hong F, Lee JC, Hammond PI, Haugabouk SP, Brimijoin S. Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003;10:491–502. doi: 10.1016/s1074-5521(03)00126-1. [DOI] [PubMed] [Google Scholar]
  • 26.Tariot PN, Jakimovich L. Donepezil use for advanced Alzheimer's disease--a case study from a long-term care facility. J Am Med Dir Assoc. 2003;4:216–219. doi: 10.1097/01.JAM.0000075830.81747.72. [DOI] [PubMed] [Google Scholar]
  • 27.Anic K, Ivandic A, Volaric M, Peric L, Getto L, Bacun T. [Cholinesterase in the differential diagnosis of parenchymal and obstructive icterus and in the differentiation between malignant and benign obstruction] Wien Med Wochenschr. 1999;149:355–358. [PubMed] [Google Scholar]
  • 28.Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery. 2002;132:620–626; discussion 620-626;. doi: 10.1067/msy.2002.127544. [DOI] [PubMed] [Google Scholar]
  • 29.Cabello G, Juarranz A, Botella LM, Calaf GM. Organophosphorous pesticides in breast cancer progression. J Submicrosc Cytol Pathol. 2003;35:1–9. [PubMed] [Google Scholar]
  • 30.Yi Z, Wang Z, Li H, Liu M. Inhibitory effect of tellimagrandin I on chemically induced differentiation of human leukemia K562 cells. Toxicol Lett. 2004;147:109–119. doi: 10.1016/j.toxlet.2003.12.008. [DOI] [PubMed] [Google Scholar]
  • 31.Bradamante V, Smigovec E, Buković D, Geber J, Matanić D. Plasma cholinesterase activity in patients with uterine cervical cancer during radiotherapy. Coll Antropol. 2000;24:373–380. [PubMed] [Google Scholar]

Articles from World Journal of Gastroenterology : WJG are provided here courtesy of Baishideng Publishing Group Inc

RESOURCES